Ratings by Wells Fargo (Benjamin Burnett)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/13/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2026 | Liquidia Technologies | LQDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2026 | Definium Therapeutics Inc | DFTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/11/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2026 | Amphastar Pharmaceuticals | AMPH | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/14/2026 | Amphastar Pharmaceuticals | AMPH | Downgrade | Equal Weight (Overweight) |
18.32 (22.96) |
25.33% | Details | |
| 5/5/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/20/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Equal Weight (Overweight) |
39.66 (40.50) |
2.12% | Details | |
| 3/10/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/3/2025 | Xenon Pharmaceuticals | XENE | New Coverage | Overweight (N/A) |
38.71 (60.00) |
55% | Details | |
| 9/3/2025 | Axsome Therapeutics | AXSM | New Coverage | Overweight (N/A) |
121.28 (202.83) |
67.24% | Details |
